传奇生物Legend Biotech（LEGN）2025年第四季度及全年业绩及近期亮点「NASDAQ」（英文版）（6页）.pdf

1、Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent HighlightsMarch 10,2026CARVYKTI(ciltacabtagene autoleucel;cilta-cel)net trade sales of approximately$555 million and$1.9 billion for thefourth quarter and full year 2025,respectivelySurpassed milestone of more than 10,000 pa

2、tients treated with CARVYKTICARVYKTI now available across 294 sites worldwide;continued expansion in U.S.community settingsAdvanced early-stage cell therapy portfolio,including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D,an allogeneic CAR-T th

3、erapyCash and cash equivalents,and time deposits of$949 million,as of December 31,2025SOMERSET,N.J.,March 10,2026(GLOBE NEWSWIRE)-Legend Biotech Corporation(NASDAQ:LEGN)(Legend Biotech),a global leader in celltherapy,today reported financial results for the fourth quarter and year ended December 31,

4、2025,and key corporate highlights.“CARVYKTI continued to build on its leadership in multiple myeloma CART in 2025,as we reached more than 10,000 patients treated and achievedfranchise profitability,”said Ying Huang,Ph.D.,Chief Executive Officer of Legend Biotech.“With expanding capacity and ongoing

5、efforts to broadenadoption,including in the community setting,we are focused on executing against the opportunities ahead while extending our innovation leadershipacross in vivo and allogeneic programs.”Key Business DevelopmentsAchieved CARVYKTI franchise profitability for the full year 2025.Treated

6、 more than 10,000 clinical and commercial patients to date with CARVYKTI.Strengthened manufacturing and supply capabilities,completing the newly expanded portion of the Raritan facility,makingit the largest cell therapy manufacturing site in the United States supporting treatment of up to 10,000 pat